Klemens Budde
Kidney and transplant physician who took part as an investigator in the EXIST-2 trial of everolimus for kidney tumours in tuberous sclerosis and LAM; clinician-investigator rather than a bench mTOR researcher.
Professor, Department of Nephrology and Internal Intensive Care, Charité Berlin · clinician and transplant specialist
Department of Internal Medicine, with a focus on Nephrology and Internal Intensive Care, Charité – Universitätsmedizin Berlin (Berlin, Germany) ↗ ORCID0000-0002-7929-5942 ↗
Portrait: Charité – Universitätsmedizin Berlin
Klemens Budde is a physician at the Charité hospital in Berlin. He works in nephrology, the medicine of the kidneys, with a focus on kidney transplantation.
Transplant doctors use mTOR inhibitors such as everolimus and sirolimus to help prevent organ rejection, so mTOR drugs are part of everyday practice in his field.
He is the last author of EXIST-2, a phase 3 trial in 118 adults with kidney tumours called angiomyolipomas, caused by tuberous sclerosis complex or by LAM. Everolimus shrank the tumours by at least half in 42 percent of treated patients and in none on placebo. He is a clinician-investigator, so his role here is on the clinical side.
Milestones in the Atlas
A selection, not a full bibliography: only papers that meet the Atlas inclusion criteria.
| Year | Evidence | Study |
|---|---|---|
| 2013 | H | Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial BIS2013 Companion phase 3 trial (EXIST-2) showing that everolimus shrank angiomyolipomas in 42% of patients versus 0% on placebo; Budde is listed as last author. |
Co-authors in the Atlas 5
People with a profile here who share at least one study with Klemens Budde.
ShowHide
- David Lebwohl Medical oncologist and drug developer who led the clinical development of everolimus (Afinitor) at Novartis through approvals in several cancers and tuberous sclerosis, and later served as Chief Medical Officer of the gene-editing company Intellia Therapeutics
- Elena Belousova Child neurologist and epilepsy specialist in Moscow who heads a department of psychoneurology and epileptology and has been a principal investigator in international drug trials for tuberous sclerosis complex
- John J. Bissler Led the first clinical trial showing that the mTOR inhibitor sirolimus shrinks kidney angiomyolipomas in tuberous sclerosis, and the EXIST-2 trial of everolimus for the same tumours
- Michael D. Frost Co-investigator on the EXIST-1 and EXIST-2 trials showing that the mTOR inhibitor everolimus shrinks tuberous sclerosis tumours in the brain and kidney
- Tarek Sahmoud Physician and epidemiologist who worked as a clinical program head in Novartis oncology drug development during the everolimus trials, and later as chief medical officer at several cancer drug companies
Every researcher with a profile →
Thank you. That helps us know which pages have been read by someone who knows the work.
Thank you. We will check it and correct the page.
Thank you. Your answer was counted anonymously.